Expansion Therapeutics is a drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases. Based on exclusive worldwide rights to groundbreaking research from the laboratory of Matthew D. Disney, Ph.D., at The Scripps Research Institute, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule binders of RNA. Through this unique platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of disease indications. The company's initial development focus is on therapies for patients with expansion repeat diseases who currently have limited and unsatisfactory treatment options.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/03/18 | $55,300,000 | Series A |
5AM Ventures Alexandria Real Estate Equities Novartis Venture Funds RA Capital Sanofi Ventures | undisclosed |
| 09/29/21 | $80,000,000 | Series B |
5AM Ventures Cormorant Asset Management Kleiner Perkins Caufield and Byers Logos Capital Novartis Venture Funds RA Capital Management Sanofi Ventures Surveyor Capital Westlake Village BioPartners | undisclosed |
